Aplenzin (bupropion hydrobromide ER) / Bausch Health - LARVOL DELTA

TTOP: Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (clinicaltrials.gov) - P2 | N=126 | Recruiting | Sponsor: Joseph Valentino, MD | N=96 ➔ 126

Enrollment change • Oncology • Tobacco Cessation

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) - P=N/A | N=1037352 | Terminated | Sponsor: University of New Mexico | Completed ➔ Terminated; Per PI, this study is not a clinical trial and was inadvertently entered in the system

HEOR • Trial termination • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

TTOP: Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (clinicaltrials.gov) - P2 | N=96 | Recruiting | Sponsor: Joseph Valentino, MD | Trial completion date: Jan 2024 ➔ Jan 2026 | Trial primary completion date: Jan 2024 ➔ Jan 2026

Trial completion date • Trial primary completion date • Oncology • Tobacco Cessation

Drugs for depressionr. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

TTOP: Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (clinicaltrials.gov) - P2 | N=96 | Recruiting | Sponsor: Joseph Valentino, MD | Trial completion date: Mar 2023 ➔ Jan 2024 | Trial primary completion date: Sep 2022 ➔ Jan 2024

Trial completion date • Trial primary completion date • Oncology • Tobacco Cessation

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) - P=N/A; N=1037352; Completed; Sponsor: University of New Mexico; Enrolling by invitation ➔ Completed

HEOR • Trial completion • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Bausch Health Companies inc (BHC) Q2 2021 Earnings Call Transcript (The Motley Fool) - "Finally, our Diversified segment, second quarter revenue of $200 million was down 7% organically. Our Neuro business was down 4%. The decline was due to LOE assets partially offset by growth in ATIVAN and APLENZIN."

Commercial • CNS Disorders • Depression • Major Depressive Disorder

Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder (clinicaltrials.gov) - P4; N=200; Not yet recruiting; Sponsor: Bausch Health Americas, Inc.; Trial completion date: Apr 2024 ➔ Nov 2024; Trial primary completion date: Apr 2024 ➔ Nov 2024

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

TTOP: Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (clinicaltrials.gov) - P2; N=96; Recruiting; Sponsor: Joseph Valentino, MD; Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Tobacco Cessation

Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder (clinicaltrials.gov) - P4; N=200; Not yet recruiting; Sponsor: Bausch Health Americas, Inc.; Trial completion date: Mar 2021 ➔ Apr 2024; Trial primary completion date: Nov 2020 ➔ Apr 2024

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

Drugs for Depression. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Depression • Mood Disorders

Bausch Health Companies Inc. (BHC) Q2 2020 Earnings Call Transcript (The Motley Fool) - "The neuro business was off 13%. Hidden in there was continued solid performance of Wellbutrin and Aplenzin, which together account for about 55% of neuro's revenues. We expected these brands to be resilient in the COVI'D world, and they were, with Wellbutrin growing 7% and Aplenzin plus 10%."

Commercial • CNS Disorders • Depression

Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder (clinicaltrials.gov) - P4; N=200; Not yet recruiting; Sponsor: Valeant Pharmaceuticals International, Inc.; Trial completion date: Dec 2017 ➔ Mar 2021; Trial primary completion date: Dec 2017 ➔ Nov 2020

Clinical • Trial completion date • Trial primary completion date